TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04683679: A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

Sponsor: Memorial Sloan Kettering Cancer Center · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 34 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,524,600

Rescue Site Savings

+$1,016,400

Unlock Full NCT04683679 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04683679 Rescue Dossier →